0000950170-24-024970.txt : 20240304 0000950170-24-024970.hdr.sgml : 20240304 20240304172540 ACCESSION NUMBER: 0000950170-24-024970 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burgess Justin CENTRAL INDEX KEY: 0001812025 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34207 FILM NUMBER: 24716101 MAIL ADDRESS: STREET 1: C/O DYNAVAX TECHNOLOGIES CORPORATION STREET 2: 2100 POWELL STREET, SUITE 1900 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP CENTRAL INDEX KEY: 0001029142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330728374 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 POWELL STREET STREET 2: SUITE 720 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5108485100 MAIL ADDRESS: STREET 1: 2100 POWELL STREET STREET 2: SUITE 720 CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 ownership.xml 4 X0508 4 2024-03-01 0001029142 DYNAVAX TECHNOLOGIES CORP DVAX 0001812025 Burgess Justin C/O DYNAVAX TECHNOLOGIES 2100 POWELL STREET, SUITE 720 EMERYVILLE CA 94608 false true false false Chief Accounting Officer false Common Stock 2024-03-01 4 M false 4334 11.12 A 17759 D Common Stock 2024-03-01 4 M false 2767 9.41 A 20526 D Common Stock 2024-03-01 4 S false 7101 12.78 D 13425 D Common Stock 2024-03-01 4 S false 13425 12.78 D 0 D Stock Options (Right to Buy) 11.12 2024-03-01 4 M false 4334 0 D 2030-02-15 Common Stock 0 8666 D StockOptions (Right to Buy) 9.41 2024-03-01 4 M false 2767 0 D 2028-02-02 Common Stock 0 0 D Code M - Exercise or conversion of derivative security Code S - Open market or private sale of non-derivative or derivative security This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax. This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. /s/ JUSTIN BURGESS 2024-03-04